[
  {
    "sentence": "When reflecting on tryptophan metabolism in brain tumors it is imperative to recognize its specific role in the brain (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Taken together, alterations in CNS tryptophan metabolism in patients with brain tumors may contribute to the multiple comorbidities of this disease (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Moreover, IFN- γ-induced tryptophan depletion has recently been demonstrated to lead to ribosomal frame shifting in melanoma, resulting in the generation of aberrant peptides that are presented on HLA-I molecules and can prime T cells, thereby possibly enhancing anti-tumor immunity [55••] (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly, upregulation of QPRT and ensuing NAD production also mediates resistance to combined treatment with the histone deacetylase inhibitor panobinostat and the proteasome inhibitor bortezomib in glioma patients [57], further underscoring how tryptophan catabolism can contribute to higher NAD levels in glioma (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Through its effects on tumor cells as well as select other immune cell subsets, AHR activation may importantly contribute to immune escape and malignancy in brain cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When reflecting on tryptophan metabolism in brain tumors it is imperative to recognize its specific role in the brain (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Taken together, alterations in CNS tryptophan metabolism in patients with brain tumors may contribute to the multiple comorbidities of this disease (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Moreover, IFN- γ-induced tryptophan depletion has recently been demonstrated to lead to ribosomal frame shifting in melanoma, resulting in the generation of aberrant peptides that are presented on HLA-I molecules and can prime T cells, thereby possibly enhancing anti-tumor immunity [55••] (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly, upregulation of QPRT and ensuing NAD production also mediates resistance to combined treatment with the histone deacetylase inhibitor panobinostat and the proteasome inhibitor bortezomib in glioma patients [57], further underscoring how tryptophan catabolism can contribute to higher NAD levels in glioma (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Through its effects on tumor cells as well as select other immune cell subsets, AHR activation may importantly contribute to immune escape and malignancy in brain cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When reflecting on tryptophan metabolism in brain tumors it is imperative to recognize its specific role in the brain (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Taken together, alterations in CNS tryptophan metabolism in patients with brain tumors may contribute to the multiple comorbidities of this disease (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Moreover, IFN- γ-induced tryptophan depletion has recently been demonstrated to lead to ribosomal frame shifting in melanoma, resulting in the generation of aberrant peptides that are presented on HLA-I molecules and can prime T cells, thereby possibly enhancing anti-tumor immunity [55••] (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly, upregulation of QPRT and ensuing NAD production also mediates resistance to combined treatment with the histone deacetylase inhibitor panobinostat and the proteasome inhibitor bortezomib in glioma patients [57], further underscoring how tryptophan catabolism can contribute to higher NAD levels in glioma (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Through its effects on tumor cells as well as select other immune cell subsets, AHR activation may importantly contribute to immune escape and malignancy in brain cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When reflecting on tryptophan metabolism in brain tumors it is imperative to recognize its specific role in the brain (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Taken together, alterations in CNS tryptophan metabolism in patients with brain tumors may contribute to the multiple comorbidities of this disease (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Moreover, IFN- γ-induced tryptophan depletion has recently been demonstrated to lead to ribosomal frame shifting in melanoma, resulting in the generation of aberrant peptides that are presented on HLA-I molecules and can prime T cells, thereby possibly enhancing anti-tumor immunity [55••] (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly, upregulation of QPRT and ensuing NAD production also mediates resistance to combined treatment with the histone deacetylase inhibitor panobinostat and the proteasome inhibitor bortezomib in glioma patients [57], further underscoring how tryptophan catabolism can contribute to higher NAD levels in glioma (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Through its effects on tumor cells as well as select other immune cell subsets, AHR activation may importantly contribute to immune escape and malignancy in brain cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When reflecting on tryptophan metabolism in brain tumors it is imperative to recognize its specific role in the brain (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Taken together, alterations in CNS tryptophan metabolism in patients with brain tumors may contribute to the multiple comorbidities of this disease (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Moreover, IFN- γ-induced tryptophan depletion has recently been demonstrated to lead to ribosomal frame shifting in melanoma, resulting in the generation of aberrant peptides that are presented on HLA-I molecules and can prime T cells, thereby possibly enhancing anti-tumor immunity [55••] (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly, upregulation of QPRT and ensuing NAD production also mediates resistance to combined treatment with the histone deacetylase inhibitor panobinostat and the proteasome inhibitor bortezomib in glioma patients [57], further underscoring how tryptophan catabolism can contribute to higher NAD levels in glioma (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Through its effects on tumor cells as well as select other immune cell subsets, AHR activation may importantly contribute to immune escape and malignancy in brain cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When reflecting on tryptophan metabolism in brain tumors it is imperative to recognize its specific role in the brain (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Taken together, alterations in CNS tryptophan metabolism in patients with brain tumors may contribute to the multiple comorbidities of this disease (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Moreover, IFN- γ-induced tryptophan depletion has recently been demonstrated to lead to ribosomal frame shifting in melanoma, resulting in the generation of aberrant peptides that are presented on HLA-I molecules and can prime T cells, thereby possibly enhancing anti-tumor immunity [55••] (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly, upregulation of QPRT and ensuing NAD production also mediates resistance to combined treatment with the histone deacetylase inhibitor panobinostat and the proteasome inhibitor bortezomib in glioma patients [57], further underscoring how tryptophan catabolism can contribute to higher NAD levels in glioma (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Through its effects on tumor cells as well as select other immune cell subsets, AHR activation may importantly contribute to immune escape and malignancy in brain cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When reflecting on tryptophan metabolism in brain tumors it is imperative to recognize its specific role in the brain (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Taken together, alterations in CNS tryptophan metabolism in patients with brain tumors may contribute to the multiple comorbidities of this disease (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Moreover, IFN- γ-induced tryptophan depletion has recently been demonstrated to lead to ribosomal frame shifting in melanoma, resulting in the generation of aberrant peptides that are presented on HLA-I molecules and can prime T cells, thereby possibly enhancing anti-tumor immunity [55••] (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly, upregulation of QPRT and ensuing NAD production also mediates resistance to combined treatment with the histone deacetylase inhibitor panobinostat and the proteasome inhibitor bortezomib in glioma patients [57], further underscoring how tryptophan catabolism can contribute to higher NAD levels in glioma (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Through its effects on tumor cells as well as select other immune cell subsets, AHR activation may importantly contribute to immune escape and malignancy in brain cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When reflecting on tryptophan metabolism in brain tumors it is imperative to recognize its specific role in the brain (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Taken together, alterations in CNS tryptophan metabolism in patients with brain tumors may contribute to the multiple comorbidities of this disease (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Moreover, IFN- γ-induced tryptophan depletion has recently been demonstrated to lead to ribosomal frame shifting in melanoma, resulting in the generation of aberrant peptides that are presented on HLA-I molecules and can prime T cells, thereby possibly enhancing anti-tumor immunity [55••] (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly, upregulation of QPRT and ensuing NAD production also mediates resistance to combined treatment with the histone deacetylase inhibitor panobinostat and the proteasome inhibitor bortezomib in glioma patients [57], further underscoring how tryptophan catabolism can contribute to higher NAD levels in glioma (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Through its effects on tumor cells as well as select other immune cell subsets, AHR activation may importantly contribute to immune escape and malignancy in brain cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "When reflecting on tryptophan metabolism in brain tumors it is imperative to recognize its specific role in the brain (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "When reflecting on tryptophan metabolism in brain tumors it is imperative to recognize its specific role in the brain (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Taken together, alterations in CNS tryptophan metabolism in patients with brain tumors may contribute to the multiple comorbidities of this disease (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Taken together, alterations in CNS tryptophan metabolism in patients with brain tumors may contribute to the multiple comorbidities of this disease (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Moreover, IFN- γ-induced tryptophan depletion has recently been demonstrated to lead to ribosomal frame shifting in melanoma, resulting in the generation of aberrant peptides that are presented on HLA-I molecules and can prime T cells, thereby possibly enhancing anti-tumor immunity [55••] (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Moreover, IFN- γ-induced tryptophan depletion has recently been demonstrated to lead to ribosomal frame shifting in melanoma, resulting in the generation of aberrant peptides that are presented on HLA-I molecules and can prime T cells, thereby possibly enhancing anti-tumor immunity [55••] (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Interestingly, upregulation of QPRT and ensuing NAD production also mediates resistance to combined treatment with the histone deacetylase inhibitor panobinostat and the proteasome inhibitor bortezomib in glioma patients [57], further underscoring how tryptophan catabolism can contribute to higher NAD levels in glioma (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Interestingly, upregulation of QPRT and ensuing NAD production also mediates resistance to combined treatment with the histone deacetylase inhibitor panobinostat and the proteasome inhibitor bortezomib in glioma patients [57], further underscoring how tryptophan catabolism can contribute to higher NAD levels in glioma (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Through its effects on tumor cells as well as select other immune cell subsets, AHR activation may importantly contribute to immune escape and malignancy in brain cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Through its effects on tumor cells as well as select other immune cell subsets, AHR activation may importantly contribute to immune escape and malignancy in brain cancer (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  }
]